Cargando…
Long-term persistence of treatment after hip fracture in a fracture liaison service
Long-term adherence to antiosteoporosis medication (AOM) in the setting of a fracture liaison service (FLS) are not well known. Patients ≥ 50 with hip fracture seen in an FLS and recommended for treatment to prevent new fractures were analyzed. Baseline data included demographics, identification mod...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174234/ https://www.ncbi.nlm.nih.gov/pubmed/35672434 http://dx.doi.org/10.1038/s41598-022-13465-x |
_version_ | 1784722195029688320 |
---|---|
author | Naranjo, Antonio Molina, Amparo Quevedo, Adrián Rubiño, Francisco J. Sánchez-Alonso, Fernando Rodríguez-Lozano, Carlos Ojeda, Soledad |
author_facet | Naranjo, Antonio Molina, Amparo Quevedo, Adrián Rubiño, Francisco J. Sánchez-Alonso, Fernando Rodríguez-Lozano, Carlos Ojeda, Soledad |
author_sort | Naranjo, Antonio |
collection | PubMed |
description | Long-term adherence to antiosteoporosis medication (AOM) in the setting of a fracture liaison service (FLS) are not well known. Patients ≥ 50 with hip fracture seen in an FLS and recommended for treatment to prevent new fractures were analyzed. Baseline data included demographics, identification mode, previous treatment and FRAX items. Patient records were reviewed 3–8 years later, and these data were collected: (1) survival; (2) major refracture; (3) initiation of treatment, proportion of days covered (PDC) and persistence with AOM. 372 patients (mean age, 79 years; 76% women) were included. Mean follow-up was 47 months, 52 patients (14%) had a refracture (22 hip) and 129 (34.5%) died. AOM was started in 283 patients (76.0%). Factors associated with initiation of AOM were previous use of bisphosphonate (OR 9.94; 95% CI 1.29–76.32) and a lower T-score lumbar (OR 0.80; 95% CI 0.65–0.99). Persistence decreased to 72.6%, 60% and 47% at 12, 36 and 60 months. A PDC > 80% was confirmed in 208 patients (55.7%) and associated with previous use of bisphosphonate (OR 3.38; 95% CI 1.34–8.53), treatment with denosumab (OR 2.69; 95% CI:1.37–5.27), and inpatient identification (OR 2.26; 95% CI 1.18–4.34). Long-term persistence with AOM was optimal in patients with hip fracture seen at an FLS. A PDC > 80% was associated with inpatient identification and prescription of denosumab. |
format | Online Article Text |
id | pubmed-9174234 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-91742342022-06-09 Long-term persistence of treatment after hip fracture in a fracture liaison service Naranjo, Antonio Molina, Amparo Quevedo, Adrián Rubiño, Francisco J. Sánchez-Alonso, Fernando Rodríguez-Lozano, Carlos Ojeda, Soledad Sci Rep Article Long-term adherence to antiosteoporosis medication (AOM) in the setting of a fracture liaison service (FLS) are not well known. Patients ≥ 50 with hip fracture seen in an FLS and recommended for treatment to prevent new fractures were analyzed. Baseline data included demographics, identification mode, previous treatment and FRAX items. Patient records were reviewed 3–8 years later, and these data were collected: (1) survival; (2) major refracture; (3) initiation of treatment, proportion of days covered (PDC) and persistence with AOM. 372 patients (mean age, 79 years; 76% women) were included. Mean follow-up was 47 months, 52 patients (14%) had a refracture (22 hip) and 129 (34.5%) died. AOM was started in 283 patients (76.0%). Factors associated with initiation of AOM were previous use of bisphosphonate (OR 9.94; 95% CI 1.29–76.32) and a lower T-score lumbar (OR 0.80; 95% CI 0.65–0.99). Persistence decreased to 72.6%, 60% and 47% at 12, 36 and 60 months. A PDC > 80% was confirmed in 208 patients (55.7%) and associated with previous use of bisphosphonate (OR 3.38; 95% CI 1.34–8.53), treatment with denosumab (OR 2.69; 95% CI:1.37–5.27), and inpatient identification (OR 2.26; 95% CI 1.18–4.34). Long-term persistence with AOM was optimal in patients with hip fracture seen at an FLS. A PDC > 80% was associated with inpatient identification and prescription of denosumab. Nature Publishing Group UK 2022-06-07 /pmc/articles/PMC9174234/ /pubmed/35672434 http://dx.doi.org/10.1038/s41598-022-13465-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Naranjo, Antonio Molina, Amparo Quevedo, Adrián Rubiño, Francisco J. Sánchez-Alonso, Fernando Rodríguez-Lozano, Carlos Ojeda, Soledad Long-term persistence of treatment after hip fracture in a fracture liaison service |
title | Long-term persistence of treatment after hip fracture in a fracture liaison service |
title_full | Long-term persistence of treatment after hip fracture in a fracture liaison service |
title_fullStr | Long-term persistence of treatment after hip fracture in a fracture liaison service |
title_full_unstemmed | Long-term persistence of treatment after hip fracture in a fracture liaison service |
title_short | Long-term persistence of treatment after hip fracture in a fracture liaison service |
title_sort | long-term persistence of treatment after hip fracture in a fracture liaison service |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174234/ https://www.ncbi.nlm.nih.gov/pubmed/35672434 http://dx.doi.org/10.1038/s41598-022-13465-x |
work_keys_str_mv | AT naranjoantonio longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT molinaamparo longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT quevedoadrian longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT rubinofranciscoj longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT sanchezalonsofernando longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT rodriguezlozanocarlos longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice AT ojedasoledad longtermpersistenceoftreatmentafterhipfractureinafractureliaisonservice |